Objective: Arterial hypertension is often associated with pathologies related with oxidative stress. Angiotensin converting enzyme (ACE) inhibitors have been used as a safe and effective treatment of hypertension and coronary heart disease. However, the significance of ACE inhibitor usage in hypertension-induced cerebrovascular and neurodegenerative diseases is still unknown. In this study, we aimed to investigate the effects of lisinopril, an ACE inhibitor, on oxidative stress and antioxidant enzyme activities in brain tissues of rats with L-NAME (N ω -Nitro-L-Arginine Methyl Ester hydrochloride) induced hypertension. Methods: Thirty-two Sprague-Dawley rats were divided into four groups: Control, L-NAME, L-NAME plus lisinopril, and only lisinopril. Hypertension was induced by oral administration of the L-NAME (75 mg/kg/day) in drinking water for 6 weeks. Rats were treated with Lisinopril (10 mg/kg/day) for six weeks. Systolic blood pressures were measured at the first, third and sixth weeks by using tail cuff method. Malondialdehyde (MDA), Superoxide dismutase (SOD), Catalase (CAT) and Glutathione peroxidase (GSH-Px) activity were measured from the brain tissue. Nitric oxide (NO) levels were measured from plasma. Results: Our results showed that L-NAME leads to an increase in systolic blood pressure of animals. The antihypertensive effect of lisinopril was observed. MDA level was significantly increased, and antioxidant enzymes activities were decreased in L-NAME given group (p<0.05). However, there was no statistically significant differences between the lisinopril given and other groups according to antioxidant enzymes activities (p>0.05). Conclusion: In our study, hypertension led to oxidative damage in brain tissues. Although lisinopril prevents the hypertension induced oxidative damage, direct antioxidant effect was not observed. Further studies are needed in order to gain certainty effect of lisinopril in brain tissue.
Introduction
Cerebrovascular and neurodegenerative disorders are among the most common causes of neurological morbidity in developed countries and hypertension is a well-defined risk factor for these insults. Some conditions induced by hypertension such as oxidative stress, inflammation and endothelial dysfunction are important factors in pathogenetic background of brain damage [1, 2] . Oxidative stress, which is characterized by increased bioavailability of reactive oxygen species, plays an important role in development and progression of cerebrovascular dysfunction associated with hypertensive disease [3] . Increased levels of reactive oxygen species such as superoxide anion, hydrogen peroxide and lipid peroxides are reported in patients with hypertension [3, 4] . Arterial hypertension is often associated with pathologies related with oxidative stress and may be considered as a result of systemic damage in different target organs or tissues induced by free radicals [5, 6] . Angiotensin Converting Enzyme (ACE) inhibitors have taken their place in clinical use as effective and safe antihypertensives and vascular protective agents [7] . Although these agents have been widely used in treatment of hypertension and congestive heart failure, there are only a few preclinical and clinical studies in which ACE inhibitors have been shown to reduce the incidence of dementia or slow down the rate of cognitive decline in patients with hypertension. Furthermore, the significance of ACE inhibitor usage in hypertension-induced cerebrovascular and neurodegenerative diseases is still unknown [8, 9] . Lisinopril, a new non-sulfhydryl ACE inhibitor which can pass through the blood-brain barrier, is absorbed in its active form and primarily excreted with urine [10] . In many studies, it has been shown that ACE and Angiotensin-II (A-II) have had many different effects on nervous system [11, 12] . A-II exerts its effect on brain tissue via Angiotensin Type-I receptors. Neuromediators such as A-II, dopamine, bradykinin, enkephalin, substance P, dynorphin and neurotensin have an effect on metabolism [13] . While being commonly found in brain tissue, ACE is mainly located in basal ganglia, periventricular areas, hippocampus, hypothalamic neurosecretory nucleus and the cerebellum [14] . The aim of this study is to investigate the possible protective effect of lisinopril against oxidative stress in cerebral tissues of rats with L-NAME (N ω -Nitro-LArginine Methyl Ester hydrochloride)-induced chronic hypertension.
Methods

Animals
A total of 32 female Sprague-Dawley rats with mean age of eight weeks and weighing between 190-220 grams were included in this study. Animals were obtained from Laboratory Animal Production Unit of Suleyman Demirel University and they were procedured, maintained and treated in accordance with the "Animal Welfare Act and the Guide for the Care and Use of Laboratory animals prepared by the Suleyman Demirel University, Animal Ethical Commitee (Date: 25.07.2006 proposal number:06/12)". Rats were placed in a room with ideal temperature (21±2°C) and humidity (60±5%), in which a 12h:12h light:dark cycle was maintained for one week prior to the initiation of the treatment. The rats were fed a standard diet and tap water ad libitum.
Experimental procedure
Animals were equally divided into four groups as follows: 1) Control group (n=8); 2) only L-NAME given group (75 mg/kg/day, n=8); 3) L-NAME plus lisinopril given group (n=8) and 4) only Lisinopril given group (10 mg/kg/day, n=8). Drugs were orally given via consumption water and the whole treatment procedure lasted for 6 weeks. At the end of the study, the rats were anaesthetized with intramuscular injection of ketamine hydrochloride (Ketalar, Eczacibasi, Istanbul, Turkey) at 50 mg/ kg dose and were sacrificed.
Chemicals
Ester hydrochloride (L-NAME) and lisinopril were purchased from SigmaAldrich (St. Louis, Missouri, USA). All other chemicals were obtained from E.Merck or HIMEDIA, India.
Model of L-NAME-induced arterial hypertension and experimental protocol
Animals were given 0.6 mg/ml dose of L-NAME via consumption water to obtain the mean daily intake of 75 mg/kg during the study period [10, 15, 16] .
Blood pressure measurements
Systolic blood pressures (SBP) were measured at the first, third and sixth weeks by using tail cuff method (IITC, model 31, Woodland Hills, CA, USA). The animals were placed in a heated chamber at an ambient temperature of 30-34 °C for 15 min and blood pressure values (1) (2) (3) (4) (5) (6) (7) (8) (9) were recorded for each animal. The lowest three readings were averaged to calculate the mean blood pressure. All recordings and data analyses were done via using a computerized data acquisition system and software.
Biochemical analysis
Excised brain samples were weighed and immediately stored at -80°C. Brain tissues were homogenized in five volumes (w/v) with 1.15 % ice-cold KCl solution [6] . Assays were performed on the supernatant of the homogenate prepared at 14,000 rpm for 30 min at +4°C. Tissue protein concentrations were measured by using the Lowry method [17] . Blood samples were collected from the inferior vena cava and plasma samples were stored in aliquots at -20°C until the batch was analyzed for NO.
Cerebral tissue lipid peroxidation level was expressed as malondialdehyde (MDA) and was measured according to the procedure described by Draper and Hadley method [18] . The principle of the method is the spectrophotometric measurement of the color generated by the reaction of 2-thiobarbituric acid-reactive substance (TBARS) with MDA. TBARS value is expressed as malonyldialdehyde equivalent. Data are shown as units nano moles per milligram (nmol/mg) protein.
Plasma nitric oxide (NO) levels were determined with Griess method [19] . The absorbance of the magenta colored azo dye that is formed from stable decomposition product, nitrite and the Griess reagent was determined at 543 nm. By constructing a standard curve from the absorbance of standards, the concentration of NO in the plasma sample was determined. The results of serum NO were expressed in µmol/L.
The determination of glutathione peroxidase (GSH-Px) activity was based on the method of Paglia and Valentine [20] . The enzymatic reaction in the tube that contained reduced nicotinamide adenine dinucleotide phosphate, reduced glutathione, and sodium azide and glutathione reductase was initiated by the addition of hydrogen peroxide and the change in absorbance at 340 nm was monitored by a spectrophotometer. Activity was given as units per milligram (U/mg) protein.
Superoxide dismutase (SOD) activity was measured according to the method of Sun et al [21] . The determination of superoxide dismutase activity was based on the reaction of xanthine with xanthine oxidase to generate superoxide radicals, which react with 2-(4-iodophenyl)-3-(4-nitrophenol)-5-phenyltetrazoliumchloride to form a red formazan dye. The superoxide dismutase activity is then determined as the degree of inhibition of this reaction. Results are expressed as units per milligram of protein (U/mg protein).
Catalase (CAT) activity was measured according to the method of Aebi [22] . The principle of the assay is based on the determination of the rate constant k (dimension: s -1 , k) of hydrogen peroxide decomposition. By measuring the absorbance change per minute, the rate constant of the enzyme was determined. Activity was given as units per milligram (U/mg) protein.
Statistical analysis
The established data were expressed as mean ± standard deviation and were analyzed via using Statistical Package for the Social Sciences version 11.5 (SPSS 11.5 for Windows, Chicago, IL, USA). The normality of the distribution was tested with Kolmogorov-Smirnov test. Because the distributions were not all characterized by normal distribution, they were analyzed by using Kruskal-Wallis H test. Differences between two groups were determined with Mann-Whitney U test. Spearman test was used to calculate whether there has been any correlation among biochemical parameters. P values less than 0.05 was considered as statistically significant.
Results
Blood pressure measurements
In Table 1 and Figure, effect of lisinopril on systolic blood pressure in rats with L-NAME induced hypertension during first, third and sixth weeks were given. It has been observed that the mean systolic blood pressure was prominently increased in animals treated with L-NAME, whereas lisinopril treatment had significantly reduced the systolic blood pressure and this protective effect was detectable at 10 mg/kg dose. There was a statistically significant difference between only L-NAME given and L-NAME plus lisinopril given groups (p < 0.01). Table 2 shows the mean cerebral MDA (thiobarbituric acid reactive substances, TBARS) levels in L-NAME induced hypertensive rats following lisinopril treatment. Rats solely treated with L-NAME exhibited a significant increment in mean MDA levels and the established mean values were 2.11 ± 0.28 nmol/mg protein and 1.13 ± 0.19 nmol/mg protein in L-NAME and control groups, respectively (p < 0.001). There was a significant decrease in MDA level (1.07 ± 0.21 nmol/mg prot) in L-NAME plus lisinopril treated group (p = 0.001).
Lipid peroxidation products
Plasma NO concentration
Mean plasma concentrations of NO were given in Table  2 . As seen from the table, the mean NO level significantly decreased in L-NAME given group; whereas there was a considerable improvement towards normal range in L-NAME plus lisinopril treated group. The mean plasma NO levels were 38.3 ± 8.9, 13.6 ± 7.9 and 24.4 ± 6.9 µmol/L in controls, L-NAME given group and L-NAME plus lisinopril administered group, respectively and there was a prominent difference between the treatment groups and controls (p < 0.001). However, there was no significant difference between L-NAME plus lisinopril and only lisinopril given groups (p = 0.689). Table 3 shows the effect of lisinopril on mean SOD, CAT and GSH-Px activity levels in tissues of rats with L-NAME induced hypertension. The mean activity levels were significantly decreased in only L-NAME given group. In L-NAME plus lisinopril treated group, there was an increment in these enzymatic antioxidants. Cerebral SOD levels were 5.1 ± 1.08 and 8.1 ± 0.72 U/ mg protein in only L-NAME given group and L-NAME plus lisinopril administered group, respectively (p = 0.0241). Mean CAT levels were found as 10.9 ± 8.2 and 13.8 ± 2.6 U/mg prot in the same treatment groups (p = 0.0082). Mean GSH-Px levels were 0.09 ± 0.01 U/mg prot in L-NAME group and 0.14 ± 0.03 U/mg prot in L-NAME plus lisinopril given group (p = 0.0091). However, there was no significant difference between these groups (p = 0.0724, p = 0.0825, p = 0.0628, respectively). * p<0.05 (Control to L-NAME, L-NAME to L-NAME & Lisinopril, and control to lisinopril) and Singh have reported that lisinopril treatment has significantly attenuated the effects of vascular dementia such as impairment of learning and memory, endothelial dysfunction and significant changes in various biochemical levels in rats with deoxycorticosterone acetate (DOCA) induced hypertension [23] . According to these authors, lisinopril may be considered as a potential pharmacological agent for the management of hypertension-induced vascular dementia. Velayutham et al. have conducted a study to investigate the effect of pretreatment with lisinopril on postoperative hypertension in patients undergoing neurosurgery for supratentorial brain tumors and the role of oxidative stress in this process [24] and found that perioperative hemodynamic changes were highly associated with oxidative stress parameters in all three groups. It was observed that lisinopril significantly decreased MDA levels, protein carbonyl content and nitrate during surgical intervention (p < 0.05), an effect which has lasted after the operation. Results established from the study by Velayutham et al. have indicated that pretreatment with angiotensin-converting enzyme inhibitor (lisinopril) could reduce postoperative hypertension in patients undergoing neurosurgery, and inhibition of oxidative stress may be a potential mechanism for this effect. Uzar et al. have reported that zofenopril significantly reduced cerebral ischemia/reperfusion induced oxidative stress as indicated by increased MDA and total oxidant status levels in brain tissues of rats [6] . Zofenopril is more lipophilic and more potent than most other ACE inhibitors. Therefore, the free-radical scavenger effect of zofenopril may be attributed to the robust inhibition mechanism against ACE. The protection may be due to the indirect prevention of oxidative stress and apoptosis. These observations suggest that zofenopril may be a clinically viable protective agent
Enzymatic antioxidants
Discussion
Our study suggests that L-NAME treatment has significantly raised the arterial systolic blood pressure of rats and lisinopril may possess robust protective effect in rats with L-NAME induced hypertension as indicated by significant decrease in mean systolic blood pressure values. We observed that lisinopril has had a protective effect against hypertension-induced oxidative damage, although, according to result of our study, it is somewhat not possible to say this agent has a direct antioxidant effect. Hypertension is associated with oxidative stress in the vascularute and is a major risk factor for stroke and cognitive abnormalities. Angiotensin II (Ang II) is the main effector peptide of the renin-angiotensin system (RAS) and plays a critical role in promoting oxidative stress in the vasculature. In the cerebral circulation, Ang II has been implicated in reactive oxygen species generation, alterations to vasomotor function, impaired neurovascular coupling, inflammation, and vascular remodeling. Furthermore, studies in humans have shown that cerebral blood flow is altered during hypertension and therapeutically targeting the RAS improves cerebral blood flow. Importantly, many of the aforementioned effects have been shown to be dependent on NADPH oxidases. Thus, Ang II, NADPH oxidases and oxidative stress are likely to play key roles in the pathogenesis of hypertension and associated cerebrovascular disease.
In our literature search, we could not find any related study conducted to reveal the possible protective effect of lisinopril on oxidative stress in brain tissues of rats with L-NAME induced hypertension. However, there were several studies about the protective effect of ACE inhibitors in cerebral injury conditions so far. Sharma against a variety of conditions where cerebral damage is a consequence of oxidative stress and apoptosis.
In the present study, we have found that L-NAME treatment has led to an increase in cerebral MDA levels.
Increased lipid peroxidation appears to be the initial destructive stage for the tissue, which can make it more susceptible to oxidative damage. L-NAME plus lisinopril treatment decreases the levels of lipid peroxidation in L-NAME rats. No change has been recorded in MDA levels in only lisinopril given group. Thus, lisinopril has had no toxic effect on brain tissue. Superoxide dismutase, catalase and glutathione peroxidase were decreased in only L-NAME given rats compared to the controls, suggesting that the defense against ROS and reactive metabolites was decreased in rats with L-NAME induced hypertension. The observed reduction in antioxidant enzyme activities found in L-NAME plus lisinopril administered rats was restored with values closer to those found in normal control rats. The increased activities of superoxide dismutase, catalase and glutathione peroxidase in L-NAME plus lisinopril treated group may be attributed to antioxidant potential of lisinopril against injury caused by free radicals. However, no increment could be achieved in antioxidant enzyme activity levels in only lisinopril given group.
In conclusion, further studies are required to find the full potential and exact mechanism of lisinopril in management of cerebrovascular and neurodegenerative diseases associated with hypertension.
